ReviewReviews in endocrine & metabolic disorders2020
The epidemiology of aggressive pituitary tumors (and its challenges).
Review in Reviews in endocrine & metabolic disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Role of Activation of PI3K/AKT/mTOR and RAF/MEK/ERK Pathways in Aggressive Pituitary Adenomas-New Potential Therapeutic Approach-A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Can acromegaly be controlled in all cases?Journal of neuroendocrinology · 2026Review
- Trade-offs in proton and photon radiotherapy for pituitary adenomas.Physics and imaging in radiation oncology · 2026Article
- Temozolomide in aggressive and metastatic pituitary tumors: a Brazilian multicenter real-world cohort study.Pituitary · 2026Article
- Aggressive and malignant pituitary tumours: does the sex matter?Pituitary · 2026Review
- Organization and resource utilization of specialized neurosurgical care for chiasmatic-sellar tumors in a metropolitan health system: a hospital-based study from Kazakhstan.Frontiers in health services · 2026Article
- Distinct gut microbial profile in PIT1 lineage PitNETs: a potential link to cognitive impairment.Chinese neurosurgical journal · 2025Article
- [Pituitary adenomas: a pathway to understanding the aggressive form. Clinical genetic analysis of potential prognostic markers in the development of aggressive pituitary adenomas].Problemy endokrinologii · 2025Article
- Observational
- The Roles of PD-L1, Ki-67, P53, and Cyclin D1 in PitNETs: Diagnostic and Prognostic Implications in a Series of 74 Patients.International journal of molecular sciences · 2025Article
- Article
- MicroRNA Is Downregulated in Invasive Non-Functioning Pituitary Adenomas.International journal of molecular sciences · 2025Article
- Pituitary adenomas: biology, nomenclature and clinical classification.Reviews in endocrine & metabolic disorders · 2025Review
- Radiological and Immunohistochemical Characteristics of PitNETs in 79 Patients Undergoing Neurosurgery.Cancers · 2025Article
- Flow cytometry immune profiling of recurrent and newly diagnosed growth hormone secreting pituitary neuroendocrine tumors: comparison of two clinical cases.BMC endocrine disorders · 2025Article
- EndoCompass Project: Research Roadmap for Pituitary and Neuroendocrine Tumor Endocrinology.Hormone research in paediatrics · 2025Review
- Grading and staging for pituitary neuroendocrine tumors.Brain pathology (Zurich, Switzerland) · 2025Review
- Molecular Basis of Aggressiveness in Pituitary Adenomas and Its Association With the Immune Microenvironment.International journal of genomics · 2025Article
- Genome-wide methylation profiling differentiates benign from aggressive and metastatic pituitary neuroendocrine tumors.Acta neuropathologica · 2024Article
- The Impact of Surgical Telementoring on Reducing the Complication Rate in Endoscopic Endonasal Surgery of the Skull Base.Diagnostics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pituitary tumors are not rare if prevalence rates from autopsy or radiological series are considered; approximately 0.5% of all pituitary adenomas will come to medical attention. Less than 0.1% of these pituitary adenomas will become malignant, and probably around 0.5% of all detected adenomas will display an aggressive course. However, the exact incidence of both aggressive pituitary adenomas and pituitary carcinomas is unknown, as most data come from series with selected patients, such as surgically treated patients, which is likely not a reflection of all patients with a pituitary adenoma. An aggressive pituitary adenoma is not well-defined; even though an overarching definition, capturing both immunohistochemical and clinical characteristics is probably not waterproof, adoption of a widely accepted definition will be very helpful to harmonize research and establish more reliable epidemiological data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.